Anne-Sophie de Faucigny
Public Communications Contact en GETLINK SE .
Perfil
Anne-Sophie de Faucigny is currently the Group Chief Communication Officer at Getlink SE.
Previously, she worked as the Director at Yposkesi from 2018 to 2021.
She is a graduate of Institut d’Études Politiques de Toulouse.
Cargos activos de Anne-Sophie de Faucigny
| Empresas | Cargo | Inicio |
|---|---|---|
| GETLINK SE | Public Communications Contact | 01/10/2022 |
Antiguos cargos conocidos de Anne-Sophie de Faucigny.
| Empresas | Cargo | Fin |
|---|---|---|
Yposkesi
 Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Director/Board Member | 01/01/2021 |
Formación de Anne-Sophie de Faucigny.
| Institut d’Études Politiques de Toulouse | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| GETLINK SE | Transportation |
| Empresas privadas | 1 |
|---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
- Bolsa de valores
- Insiders
- Anne-Sophie de Faucigny
